Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027)  by Hesketh, Paul J. et al.
ORIGINAL ARTICLE
Sequential Vinorelbine and Docetaxel in Advanced Non-
small Cell Lung Cancer Patients Age 70 and Older and/or
with a Performance Status of 2: A Phase II Trial of the
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Background: This phase II study (S0027) evaluated the efficacy
and tolerability of planned sequential single-agent chemotherapy
with vinorelbine followed by docetaxel in patients with advanced
non-small cell lung cancer (NSCLC) age 70 and older and/or a
performance status (PS) of 2.
Methods: Patients with stage IIIB (pleural effusion) or stage IV
NSCLC, age 70 and older with a PS of 0-1 or 2, any age, received
three cycles of vinorelbine 25 mg/m2 days 1 and 8 every 21 days
followed by three cycles of docetaxel 35 mg/m2 days 1, 8, and 15
every 28 days.
Results: A total of 125 patients entered the study; 117 patients were
assessable for response, survival, and toxicity. Seventy-five patients
were in stratum1 (age 70 and older, PS 0-1) and 42 patients in
stratum 2 (PS 2, any age). Objective response was 19% (95%
confidence interval [CI]: 11%–30%) and 11% (95% CI: 3%–25%) in
strata 1 and 2, respectively. Median survival was 9.1 months (95%
CI: 7.1–12.7) and 5.5 months (95% CI: 3.1–6.5) in strata 1 and 2,
respectively. Survival at 12 months was 41% and 13% in strata 1 and
2, respectively. Grade 3/4 neutropenia was seen in 32% and 31% of
patients in strata 1 and 2, respectively. Three deaths probably related
to treatment were noted: one in stratum 1 and two in stratum 2.
Conclusion: Sequential vinorelbine and docetaxel is a well-toler-
ated and effective regimen in comparison with reports of other
treatments tested in patients with advanced NSCLC age 70 and older
and/or with a PS of 2.
Key Words: Lung cancer, Phase II clinical trial, Chemotherapy,
Elderly, Performance status 2.
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Treatment options for patients with advanced non-smallcell lung cancer (NSCLC) remain inadequate at the
present time. Meta-analyses have demonstrated a modest
survival benefit for cisplatin-based combination chemother-
apy regimens when compared with supportive care alone.1–4
The majority of patients in these clinical trials were younger
than the age of 65, had a good performance status (PS), and
had few major comorbid conditions. The value of chemother-
apy in other populations with advanced NSCLC such as
the elderly, patients with a poor PS, and those with defined
comorbid conditions has until recently received scant
attention.
Individuals older than age 65 comprise a disproportion-
ately large share of the patient population with newly diag-
nosed cancer, including NSCLC. Despite the preponderance
of older individuals with cancer, cooperative group trials in
the United States enroll relatively modest proportions of
elderly patients (defined here as age 70 and older). An
analysis conducted by the Southwest Oncology Group
(SWOG) demonstrated that only 13% of all patients enrolled
into SWOG trials were age 70 and older, although the overall
proportion of United States cancer patients age 70 and older
during that time period was 47%.5 When analyses are con-
fined to lung cancer, the proportion of patients age 70 and
older entered into recent cooperative group trials in advanced
NSCLC in the United States has, with rare exception, been
20%.6–9
Recently, a number of prospective trials targeting older
patients with advanced NSCLC have been reported.10–14
These trials have demonstrated the value of modern single-
agent chemotherapy and on balance would suggest no advan-
tage for nonplatinum combinations versus single-agent ther-
apy. Vinorelbine, gemcitabine, and the taxanes all appear to
be useful and well-tolerated agents. Retrospective subset
analyses from recent cooperative group trials suggest reason-
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able tolerance and potential benefit for platinum-based com-
binations in older patients as well.6–9 To date, however, no
prospective trial comparing a single agent with a platinum-
based combination has been reported in older patients with
advanced NSCLC.
Patients with a PS of 2 comprise another substantial
subset of the advanced stage NSCLC population that until
recently has been largely excluded from clinical trials. The
prognostic importance of an impaired performance status in
NSCLC is well established. A trial performed by the Eastern
Cooperative Oncology Group (ECOG) in the early 1980s
evaluating four different chemotherapy regimens demon-
strated median survival times of 36, 26, and 10 weeks for PS
0, 1, and 2 patients, respectively.15 Subset analyses from a
number of other trials also suggested that chemotherapy
results in excessive toxicity and limited treatment benefit in
the PS 2 population. Recently, interest in the role of chemo-
therapy for PS 2 patients with NSCLC has also increased due
to the availability of a number of well-tolerated newer agents
such as vinorelbine and docetaxel.14,16–18 In addition, a ret-
rospective analysis from a recently reported phase III trial
comparing the combination of paclitaxel plus carboplatin
with paclitaxel alone revealed a similar degree of benefit for
the combination versus the single agent in both good PS
patients and in PS 2 patients.9 Nevertheless, virtually no
prospective trials targeting PS 2 patients have been conducted
to date. Therefore, there is a paucity of data to guide clini-
cians on both the potential value and tolerability of chemo-
therapy in this patient population.
One approach to potentially maximize therapeutic ben-
efit while maintaining excellent tolerance involves the use of
drugs with demonstrated value as single agents in a
planned sequential fashion rather than concurrently. Mod-
els described by Day and by Norton and Simon, as well as
preliminary clinical data, support the concept that sequen-
tial administration of chemotherapeutic agents may be a
superior approach to concurrent administration.19–23 Both
models postulate that the planned substitution of new
drugs before the emergence of clinical resistance may be a
viable alternative to concurrent administration of the same
agents. Recent trials in breast-cancer and NSCLC suggest
benefit for the sequential administration of chemotherapy
agents.24,25
With this background, we initiated a trial of planned
sequential single-agent chemotherapy in patients with ad-
vanced NSCLC age 70 and older and/or with a PS of 2. Given
the experience with vinorelbine and docetaxel as first-line
therapy in these patient populations, the proven activity of
docetaxel as second-line therapy in NSCLC, and our use of
docetaxel sequentially in S9504 and S9806, these agents
were deemed appropriate for sequential use in this trial.
Therefore, it was elected to employ a schedule of three
cycles of vinorelbine followed by three cycles of docetaxel
in the current study. In addition to the usual endpoints of
survival and disease response, a patient report of the
impact of treatment was also incorporated into the study
design.
PATIENTS AND METHODS
Eligibility
Patients were required to have histologically or cyto-
logically documented newly diagnosed selected stage IIIB
(malignant pleural effusion or multiple lesions in a single
lobe) or stage IV advanced NSCLC or recurrent disease after
previous surgery and/ irradiation. Patients had to meet one of
the two following criteria: (1) age 70 and older and a Zubrod
PS of 0-1 or (2) a Zubrod PS of 2, any age. All patients were
required to have measurable or nonmeasurable but assessable
disease, be 18 years of age and older, and have acceptable
hepatic and hematologic function. Patients with brain metas-
tases, grade 2 and higher symptomatic neuropathy, previous
chemotherapy or biological therapy for NSCLC, or active
pregnancy were ineligible for inclusion in the trial. The study
was approved by the institutional review boards of the re-
spective institutions, and all patients gave written informed
consent.
Treatment Plan
Patients received vinorelbine 25 mg/m2 intravenously
on days 1 and 8 of a 21-day cycle for three cycles, followed
by docetaxel 35 mg/m2 on days 1, 8, and 15 of a 28-day cycle
for three cycles. Patients with early evidence of disease
progression before receiving all three cycles of vinorelbine
were to be immediately sequenced to docetaxel. Treatment
was limited to six total cycles of therapy. Treatment at the
time of disease recurrence or progression after six cycles was
at the discretion of each treating physician.
Dose Modifications
Patients experiencing a nadir granulocyte count of
500/L or a nadir platelet count of 50,000/L or requir-
ing a 2-week or longer delay in hematologic recovery were
required to undergo a 25% dose reduction. Treatment was
omitted on day 8 and/or day 15 if the absolute granulocyte
count was 1500/L and/or the platelet count was
100,000/L. Patients who experienced grade 2 or higher
neurologic toxicity had treatment held until symptoms
reached grade 0-1. If time to recovery was 4 weeks or longer,
the patient was removed from the study. Patients who again
experienced grade 2 or higher neurologic toxicity with re-
treatment were removed from protocol. Dose modifications
for hepatic dysfunction related to docetaxel were specified in
the protocol. For other toxicities, doses were either held for
patients with grade 2-3 toxicities or decreased by 25% (de-
pending on the nature of the toxicity). For patients with grade
4 toxicity, doses were held until resolution of the toxicity to
grade 1 or lower.
Response and Toxicity Criteria
Patients were evaluated for disease response after three
cycles of vinorelbine and again after three cycles of do-
cetaxel. Response was assessed using RECIST (Response
Evaluation Criteria in Solid Tumors) criteria,26 and toxicities
were assessed using National Cancer Institute Common Tox-
icity Criteria Version 2.0.27
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Ancillary Treatment
During docetaxel treatment, patients also received
dexamethasone 4 mg orally for three doses (the evening
before treatment, the morning of treatment, and the evening
of the day of treatment). Patients developing fluid retention
related to docetaxel could receive diuretics at the discretion of
the investigator. The routine use of granulocyte colony–
stimulating factor was not permitted. Erythropoietic growth
factors were permitted.
Patient Report Measures
Functional and symptom status
The Functional Assessment of Cancer Therapy–Lung
(FACT-L) is a validated tool used in lung cancer clinical
trials and has documented psychometric properties including
sensitivity to change.28–32 Given that patients in this study
could have a PS of 2 and/or be 70 years of age and older, we
used an abbreviated version of the FACT-L that would reduce
patient burden. The Trial Outcome Index (TOI) includes
three subscales from the FACT-L; seven functional, seven
physical well-being, and seven lung cancer– specific
items.29,30 The primary patient-reported outcome measure
was the FACT-L TOI total score; higher scores reflect better
functional and symptom status. The FACT-L TOI was com-
pleted by patients prestudy and at the beginning of cycles 2
through 6 and at completion of protocol treatment after the
third dose of docetaxel for a total of seven assessments.
Comorbidity
The Medical Conditions Questionnaire developed by
Katz et al.33 was administered once at study entry for use as
a covariate in analyses. The scoring algorithm based on the
Katz et al. scoring system incorporates severity of medical
conditions; higher scores reflect more severe comorbid con-
ditions. We also calculated a count of organ systems affected
by a medical condition.
Statistical Considerations
The main objective of the study was to test whether the
sequential combination of vinorelbine and docetaxel has
promise in terms of increasing survival in the advanced
NSCLC subsets of elderly patients with PS 0-1 and PS 2
patients of any age and to distinguish any differences between
these two subsets in terms of efficacy and toxicity. Because it
is assumed that PS 2 patients have a poorer prognosis,
patients were accrued into two strata: stratum 1, age 70 and
older, PS 0-1; stratum 2, PS 2, any age.
In stratum 1, the regimen would be considered prom-
ising if the true median survival from registration was 6
months in conjunction with acceptable toxicity and would be
considered of no further interest if the true median survival
was 4 months. With 55 patients accrued over 18 months,
an additional 1-year follow-up and assuming exponential
survival, the power of a one-sided 0.05 level test of 4- versus
6-month survival is at least 0.90. In stratum 2, the regimen
would be considered promising if the true median survival
from registration was 4 months in conjunction with accept-
able toxicity and would be considered of no further interest if
the true median survival was 2.5 months in conjunction
with acceptable toxicity. With 40 patients accrued over 12
months, an additional 1-year follow-up and assuming expo-
nential survival, the power of a one-sided 0.05 level test of
2.5- versus 4-month survival is 0.90 or higher. Exploratory
analyses were planned on the association of patient charac-
teristics, such as age, PS, and comorbidity with survival,
response rate, functional and symptom status, dose delivered,
and toxicities.
Patient-reported outcomes: Fact-L TOI
FACT-L TOI submission rates were calculated for the
two strata to indicate the proportion of forms submitted given
that the patient was alive at a particular assessment time
point. Linear mixed models for longitudinal data were em-
ployed for a first examination of the patient report of func-
tional status data.34 The patient reported outcomes analysis is
preliminary, with ongoing determination of the robustness to
different nonignorable missing data mechanisms.
Patient-reported outcomes: comorbidity
We examined the ability of patient-reported comorbid
medical conditions to predict survival for patients within each
stratum. Katz scores and counts of affected organ systems
were used to indicate level of comorbidity; results were
similar with both organ counts and the Katz et al. comorbid
medical conditions score incorporating severity. The organ
systems count and Katz scores were dichotomized as 0 or1
organ systems and 0 or 1, respectively, for survival com-
parisons.
RESULTS
Patient Characteristics
Between September of 2001 and June of 2003, 125
patients were registered in the study. Seven patients were
ineligible for the following reasons: baseline disease assess-
ments outside of time frame,3 brain metastases at baseline,1
staging criteria not met,2 NSCLC histology not demonstrat-
ed.1 One additional patient did not receive any treatment
(refused after consenting) and is not assessable. Characteris-
tics of 117 eligible patients assessable for response/survival
and toxicity are displayed in Table 1. Seventy-five patients
were entered into stratum 1 (age 70 and older, PS 0-1) and 42
patients were entered into stratum 2 (PS 2, any age). Most
patients (85%) had stage IV disease. The most common
histologic subtype was adenocarcinoma, present in 50% of
patients. Median age in strata 1 and 2 were 75 and 73 years,
respectively. Twenty-three patients (20%) were age 80 years
and older. Similar proportions of men (54%) and women
(46%) participated in the trial.
Treatment Received
Treatment was completed as planned (six cycles) in 36
(48%) and 16 (38%) of patients in strata 1 and 2, respectively.
The median number of cycles received was five in both strata.
Thirty-one (41%) and 12 (29%) patients required dose reduc-
tions in strata 1 and 2, respectively.
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Comorbidity
Patients 70 years of age and older with a PS of 0-1 and
a Katz score of 0 (n  34) had a median survival of 11
months, whereas those with a score 1 (n  41) had a
median survival of 8 months (p  0.31). When analyzed by
number of organ systems affected by comorbid conditions in
this stratum, those with no comorbidities (n  20) had a
median survival of 13 months, and those with one or more
affected organ systems (n55) had a median survival of 8
months (p  0.19). In PS 2 patients, those with a Katz score
of 1 (n  11) had a median survival of 6 months, whereas
those with a Katz score of 0 (n  31) had a median survival
of 3 months (p  0.07).
Toxicity
Treatment related toxicity (grade 3 or higher) is dis-
played in Table 2. Grade 3/4 neutropenia was seen in 32%
and 31% of patients in strata 1 and 2 respectively. Other
grade 3/4 adverse events were uncommon with the exception
of fatigue and dyspnea. Three deaths probably related to
treatment were noted. One patient in stratum 1 died of
pneumonia. In stratum 2, there were two treatment related
deaths: one patient with respiratory failure; one patient with
renal failure, dyspnea and a cardiac conduction abnormality.
Fourteen patients (19%) in the over-70 stratum and three
patients (7%) in the PS-2 stratum went off study because of
adverse events.
Response And Survival
Objective response to treatment for patients with mea-
surable disease is displayed in Table 3. Fourteen patients
(19%) (95% CI: 11%–30%) in the 70 years of age and older
stratum and four patients (11%) (95% CI: 3%–25%) in the PS
2 stratum achieved partial responses. Fourteen patients in the
70 years of age and older stratum and five patients in the PS
2 stratum had inadequate assessments of response and are
presumed nonresponders. Reasons for inadequate assessment
were early discontinuation of treatment before the first dis-
ease assessment (nine cases), inability to assess due to a
collapsed lung (one case), inadequate imaging of the primary
tumor (one case), failure to properly follow all target and
nontarget lesions (eight cases). Six patients were without
measurable disease at trial entry and are not included in the
calculation of a response rate. Median follow-up for surviv-
ing patients in strata 1 and 2 is 13.0 months (minimum, 6.3;
maximum, 23.1) and 10.4 months (minimum, 7.0; maximum,
13.5), respectively. Median progression-free survival was 4.7
months (95% CI: 2.7-5.2 months) and 2.6 months (1.9-4.2
months) in strata 1 and 2, respectively. Figure 1 graphically
displays overall survival. Median survival was 9.1 months
(95% CI: 7.1–12.7) and 5.5 months (95% CI: 3.1–6.5
months) in strata 1 and 2, respectively. Survival at 12 months
was 41% and 13% in strata 1 and 2, respectively. Survival at
24 months was 13% and 5% in strata 1 and 2, respectively.
Functional and Symptom Status
Submission rates (defined as the proportion of submit-
ters among patients alive at each time point) for the seven
FACT-L TOI assessments were as follows: stratum 1 (pre-
study [100%]; weeks 4 [85%], 7 [82%], 10 [76%], 14 [69%],
18 [72%], and week 22 [51%]); stratum 2 (prestudy [100%];
weeks 4 [81%], 7 [82%], 10 [78%], 14 [88%], 18 [76%], and
22 [60%]). The percentage of patients submitting all required
forms was not statistically different for the two strata (26%
versus 24%).
Figure 2 shows the regression line from a linear mixed
model of FACT-L score by assessment time, plotted over the
mean FACT-L TOI scores at each time point, separately for
each stratum. Patients in stratum 2 were more compromised
at study entry than those in stratum 1: the stratum 2 mean
TABLE 1. Patient Characteristics
Stratum
Variable 1a 2b
Total no. of patients 75 42
Gender, % male/female 53/47 55/45
Median age, y (range) 76 (70–88) 73 (44–85)
Stage, % IIIB/IV 14/86 15/85
Pathology, patients (%)
Adenocarcinoma 37 (49) 21 (50)
Squamous 15 (20) 14 (33)
Large cell/other 22 (31) 7 (16)
a Age 70 years and older, performance status 0-1. b Any age, performance status 2.
TABLE 2. Toxicity
Stratum 1a
(n  75)
Stratum 2b
(n  42)
Grade 3 Grade 4 Grade 3 Grade 4
Anemia 2 (3%) 1 (1%) 3 (7%) 0
Fatigue/malaise 14 (19%) 2 (3%) 6 (14%) 1 (2%)
Febrile neutropenia 4 (5%) 0 1 (2%) 0
Nausea 4 (5%) 0 2 (5%) 0
Neutropenia 15 (20%) 9 (12%) 6 (14%) 7 (17%)
Sensory neuropathy 0 0 1 (2%) 0
Thrombocytopenia 0 0 0 0
Maximal grade, any
toxicity
38 (51%) 19 (25%) 20 (48%) 11 (26%)
a Age 70 years and older, performance status 0-1. b Any age, performance status 2.
TABLE 3. Response
Stratum 1a
(n  74)
Stratum 2b
(n  37)
Complete response 0 0
Partial response 14 (19%; 95%
CI: 11%–30%)
4 (11%; 95%
CI: 3%–25%)
Stable disease 22 (30%) 10 (27%)
Increasing disease 23 (31%) 16 (43%)
Assessment inadequate 14 (19%) 5 (14%)
Early death 1 (1%) 2 (5%)
a Age 70 years and older, performance status 0-1. b Any age, performance status 2.
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FACT-L TOI score of 49.0 at baseline was 8 points lower
(worse) than the stratum 1 mean FACT-L TOI score of 57.1.
This same level of difference was present at week 22. The
negative slope shown in Figure 2 represents deteriorating
FACT-L TOI scores over the 22 week-period, with a steeper
slope observed for stratum 2. The mean differences between
weeks 0 and 22 were very similar for patients in the two
strata, -3.6 for patients in stratum 1 and -3.3 for patients in
stratum 2.
DISCUSSION
This is the first prospective clinical trial conducted by
the Southwest Oncology Group targeting patients with ad-
vanced stage NSCLC age 70 years and older or with a PS of
2. Sequential vinorelbine and docetaxel was a well-tolerated
treatment in both patient strata.
Patients age 70 years and older with a good PS (0-1)
had an improved survival compared with the PS 2 cohort. The
median survival of 9.1 months in good PS elderly patients is
comparable with the survival noted with single-agent vinorel-
bine in the ELVIS trial and single-agent vinorelbine or
gemcitabine in the MILES trial.10,12 In addition, survival
compares favorably with the results obtained in randomized
trials with platinum-based combination chemotherapy for
patients of any age.35–37
A number of reports have suggested that further prog-
nostic information can be attained by carefully recording, in
addition to PS, the extent of comorbidity.38–40 Within the
cohort of patients age 70 years and older with a good PS, we
noted that increasing comorbidity was associated with short-
ened survival, although the difference did not reach statistical
significance. Conversely, in the PS 2 stratum, a trend for
better survival with increasing comorbidity was noted. This
counterintuitive finding was not due to a predominance of
younger patients in the PS 2 stratum, but more likely repre-
sents an unstable finding based on the small sample size of
this stratum. Alternatively, there may be a cohort of patients
whose PS 2 status is based on stable comorbidities that are
not cancer related. This group may have an intrinsically better
prognosis than patients who have a PS of 2 that is directly
related to the underlying cancer. We recommend careful
assessment of comorbidity as an essential component of
future prospective trials in these subsets of advanced stage
NSCLC. In addition, for patients with a PS of 2, it might be
useful to define whether the impaired PS is primarily related
to the underlying cancer or stable comorbidities.
Previous reports in advanced NSCLC have noted im-
provements in patient-reported quality of life (particularly
symptom status) with chemotherapy treatment.10,41,42 Not
unexpectedly, the strongest finding of the current trial regard-
ing patient-reported outcomes was that patients with poorer
FIGURE 2. Functional Assessment of
Cancer Therapy–Lung (FACT-L) Trial
Outcome Index (TOI) scores by stra-
tum: stratum 1 (performance status 
0 or 1, age 70 and older); stratum 2
(performance status  2, any age).
The mean FACT-L TOI score with
standard error bars at each time point
(●). The solid line indicates the regres-
sion line from a longitudinal mixed
effects model of FACT-L TOI scores
over time. The sample size at each
time point is provided. QOL, quality
of life.
FIGURE 1. Overall survival for the 75 and 42 eligible pa-
tients in strata 1 and 2, respectively.
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baseline performance status reported a worse functional sta-
tus (FACT-L TOI score) than did patients with better baseline
PS; this pattern was also observed at the end of the second
treatment period. In both cases, differences of 8 points were
observed favoring patients with better PS. Differences of 5
points have been shown to be clinically significant for the
FACT-L TOI.32 A general trend for deterioration in scores
over the 22-week treatment period was noted in both strata.
However, the mean score differences at 22 weeks of 3.6 and
3.3 in strata 1 and 2, respectively, would not be regarded as
clinically significant. It is difficult to attribute change in
FACT-L TOI scores to either time (expected deterioration
over time in advanced stage disease) or to the addition of a
second treatment because the study design confounds these
two variables. In addition, these preliminary results may not
adequately reflect the impact of missing data on estimates of
change in functional status; additional analyses are currently
underway to examine more thoroughly potential biases asso-
ciated with missing data.
At present, it is clear from prospective trials that pa-
tients older than the age of 70 with advanced stage NSCLC
and a good PS will achieve substantial benefit with single-
agent chemotherapy using an active modern agent such as
vinorelbine and gemcitabine. Our results, albeit in a phase II
trial, suggest that sequential use of vinorelbine and docetaxel
is another viable option for these patients. The potential
advantage of additional concurrent agents is unclear. Retro-
spective subset analyses from a number of phase III trials
suggest superiority for combination platinum-based therapy
compared with single agents in both younger and older
patients.8,9 Prospective trials are needed, however, to estab-
lish whether platinum-based combination therapy is associ-
ated with improved survival and acceptable toxicity com-
pared with single-agent chemotherapy in elderly patients with
a good PS.
The large proportion of patients with advanced stage
NSCLC and a PS of 2 remains a significant therapeutic
challenge. The value of chemotherapy in this cohort of
patients has never been demonstrated in a prospective trial
compared with supportive care alone. In the ELVIS trial
comparing vinorelbine with best supportive care in patients
age 70 years and older, a small proportion of patients had a
PS of 2. Analysis of survival in this subset of patients
suggests value for active treatment.17 Median survival was 26
weeks and 8 weeks in the cohort of patients receiving vi-
norelbine and best supportive care, respectively. As is the
situation with elderly patients with a good PS, the potential
value of combination chemotherapy in PS 2 patients has
never been definitively proven. Retrospective analyses of
phase III trials of platinum-based therapy in advanced
NSCLC have consistently shown median survival for PS 2
patients of 4 months.9,43,44 In addition, many of these trials
have shown enhanced toxicity in PS 2 patients.15,45 A recent
example is ECOG (Eastern Clinical Oncology Group) 1594,
a comparison of four modern platinum-based doublets.37
Study entry criteria initially included PS 2. However, accrual
to this cohort was suspended after an interim analysis re-
ported excessive toxicity. Although a subsequent analysis
suggested that most deaths in the PS 2 population were not
treatment related, significant grade 3/4 toxicities were noted.
Grade 3/4 neutropenia ranged between 47% and 60% for the
four study arms. Most importantly, median survival was only
4.1 months. Retrospective analysis of another recent phase III
trial suggests possible superiority for combination compared
with single-agent chemotherapy. Cancer and Leukemia
Group B (CALGB) trial 9730 was a phase III study compar-
ing paclitaxel with the combination of carboplatin/paclitaxel.9
Eighteen percent of patients enrolled had a PS of 2. Analysis
of outcome in this group revealed a longer median survival
(4.7 months versus 2.4 months) in the group receiving com-
bination versus single-agent therapy.
Our experience with sequential vinorelbine and do-
cetaxel in PS 2 patients compares favorably with the ECOG
and CALGB trials. The study regimen was tolerable and
resulted in a promising median survival of 5.5 months. Two
other prospective trials targeting exclusively PS 2 patients
with advanced NSCLC have recently been reported in pre-
liminary form.45,46 The Hellenic Cooperative Oncology
Group compared gemcitabine with a combination of gemcit-
abine and carboplatin. Median survival was 4.8 and 6.7
months on the single-agent and combination arms, respec-
tively (p  0.49).45 ECOG, attempting to build on their
experience from ECOG 1594, performed a randomized phase
II trial (ECOG 1599) randomizing patients to receive either
paclitaxel/carboplatin or gemcitabine/cisplatin, each given at
attenuated doses. Hematologic toxicity was reduced with the
lower chemotherapy doses compared with the ECOG 1594
historical control and median survival was 6.1 and 6.8 months
on the paclitaxel/carboplatin and gemcitabine/cisplatin arms,
respectively.46
Unresolved issues for future prospective trials in PS 2
patients include definitive comparisons of combination versus
single-agent chemotherapy, determining the potential role of
new molecular-targeted agents and more precise identifica-
tion of the PS 2 population, incorporating comorbidity as-
sessments. In addition, it is critically important to carefully
assess symptom status in this patient population. A number of
previous studies have suggested symptom improvement even
in the absence of clear-cut survival improvement in PS 2
patients.47–50 The Southwest Oncology Group is currently
conducting a trial of single-agent erlotinib alone in previously
untreated patients with a PS of 2 with this objective in place.
In conclusion, a regimen of sequential vinorelbine and
docetaxel is well tolerated and effective in comparison with
reports of other regimens tested in patients with advanced
NSCLC age 70 years and older and/or with a PS of 2. Elderly
patients with a good PS have improved survival compared
with PS 2 patients receiving this regimen. Survival in the PS
2 stratum compares favorably with the results with previous
platinum-based regimens, although alternative approaches
clearly are needed for this patient population.
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